GlassScriptPhysician profile
Ningxin Zeng
NPI 1376595637
$4,205.65
in general payments reported to CMS, 2019-2025
33 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $489 · 2021: $363 · 2022: $629 · 2023: $355 · 2024: $1,133 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.19 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $702.02 | 2019-2025 | Linzess |
| Janssen Biotech, INC. | $568.35 | 2021-2025 | Tremfya, Stelara |
| Pfizer INC. | $468.26 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.74 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $399.64 | 2019-2025 | Entyvio |
| Lilly USA, LLC | $232.98 | 2020-2025 | Omvoh, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $190.09 | 2024-2025 | Voquezna |
| Celgene Corporation | $186.74 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $147.55 | 2023-2025 | Ibsrela |
| Allergan, INC. | $105.52 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $85.22 | 2020-2021 | |
| Braintree Laboratories, INC. | $78.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.04 | 2019-2020 | |
| Shionogi INC | $56.44 | 2019-2020 | |
| Amgen INC. | $52.89 | 2019-2025 | Repatha |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45.19 | 2019-2024 | |
| Philips North America LLC | $42.28 | 2024-2025 | Mcot, (Ck4) Mcot |
| Alnylam Pharmaceuticals INC. | $38.88 | 2022-2024 | Oxlumo |
| Regeneron Healthcare Solutions, INC. | $32.62 | 2025 | Dupixent |
| Exact Sciences Corporation | $31.55 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $30.66 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $27.54 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $25.86 | 2025 | |
| Ferring Pharmaceuticals INC. | $25.34 | 2019-2020 | |
| Celltrion USA INC. | $21.96 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $20.95 | 2025 | Rezdiffra |
| United Therapeutics Corporation | $18.00 | 2024 | Orenitram |
| Hologic Sales and Service, LLC | $16.43 | 2024 | Coolseal Generator |
| Redhill Biopharma INC. | $15.21 | 2023 | Talicia |
| Ironwood Pharmaceuticals, INC | $14.92 | 2020 | |
| Echosens North America, INC. | $14.51 | 2025 | Fibroscan |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2023 | Seglentis |
| Capsovision, INC. | $13.60 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ningxin Zeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.